
DiaMedica Therapeutics Reaches 75% Enrollment Milestone in Phase 2/3 ReMEDy2 Acute Ischemic Stroke Trial
DiaMedica Therapeutics announced that it has reached approximately 75% enrollment in its ReMEDy2 Phase 2/3 acute ischemic stroke trial, marking a key development milestone in the study. DiaMedica Therapeutics Inc.…












